The effect of DNA mismatch repair (MMR) status on oxaliplatinbased first-line chemotherapy as in recurrent or metastatic colon cancer

Medical Oncology

Volumn 27, Issue 4, 2010, Pages 1277-1285

  Kim, Seung Tae ^a   Lee, Jeeyun ^a   Park, Se Hoon ^a   Park, Joon Oh ^a   Lim, Ho Yeong ^a   Kang, Won Ki ^a   Kim, Jin Yong ^a   Kim, Young Ho ^a   Chang, Dong Kyung ^a   Rhee, Poong Lyul ^a   Kim, Dae Shick ^a   Yun, Haeran ^a   Cho, Yong Beom ^a   Kim, Hee Cheol ^a   Yun, Seong Hyeon ^a   Chun, Ho Kyung ^a   Lee, Woo Yong ^a   Park, Young Suk ^a  

^a Sungkyunkwan University   (South Korea)

Author keywords

CAPOX; FOLFOX; MMR; MSI

Indexed keywords

CAPECITABINE; FLUOROURACIL; OXALIPLATIN; PROTEIN MLH1; PROTEIN MSH2;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; COLON CANCER; CONTINUOUS INFUSION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DNA MISMATCH REPAIR; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; INFUSIONS, INTRAVENOUS; LEUCOVORIN; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; POLYMERASE CHAIN REACTION; PROGNOSIS; SURVIVAL RATE; YOUNG ADULT;

EID: 79951768387     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-009-9374-x     Document Type: Article

References (43)

1. Gervaz P, Bucher P, Morel P. Two colons-two cancers: paradigm shift and clinical implications. J Surg Oncol. 2004;88:261-6. (Pubitemid 39601269)
2. Gervaz P, et al. Comparison of microsatellite instability and chromosomal instability in predicting survival of patients with T3N0 colorectal cancer. Surgery. 2002;131:190-7. (Pubitemid 34169546)
3. Haydon AM, Jass JR. Emerging pathways in colorectal-cancer development. Lancet Oncol. 2002;3:83-8. (Pubitemid 34162978)
4. Jass JR, Whitehall VL, Young J, Leggett BA. Emerging concepts in colorectal neoplasia. Gastroenterology. 2002;123:862-76. (Pubitemid 34977092)
5. Aaltonen LA, et al. Clues to the pathogenesis of familial colorectal cancer. Science. 1993;260:812-6. (Pubitemid 23167611)
6. Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature. 1993;363:558-61. (Pubitemid 23186645)
7. Soreide K, Janssen EA, Soiland H, Korner H, Baak JP. Microsatellite instability in colorectal cancer. Br J Surg. 2006;93:395-406.
8. Miyakura Y, et al. Extensive but hemiallelic methylation of the hMLH1 promoter region in early-onset sporadic colon cancers with microsatellite instability. Clin Gastroenterol Hepatol. 2004;2:147-56. (Pubitemid 38180469)
9. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349:2042-54. (Pubitemid 37448928)
10. Herman JG, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA. 1998;95:6870-5. (Pubitemid 28278073)
11. Jass JR, et al. Morphology of sporadic colorectal cancer with DNA replication errors. Gut. 1998;42:673-9. (Pubitemid 28261055)
12. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science. 1993;260:816-9. (Pubitemid 23167612)
13. Lothe RA, et al. Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. Cancer Res. 1993;53:5849-52. (Pubitemid 24006146)
14. Gryfe R, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med. 2000;342:69-77. (Pubitemid 30036597)
15. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005;23:609-18. (Pubitemid 46224239)
16. Anthoney DA, McIlwrath AJ, Gallagher WM, Edlin AR, Brown R. Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells. Cancer Res. 1996;56:1374-81.
17. Gradia S, Acharya S, Fishel R. The role of mismatched nucleotides in activating the hMSH2-hMSH6 molecular switch. J Biol Chem. 2000;275:3922-30. (Pubitemid 30094617)
18. Kat A, et al. An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair. Proc Natl Acad Sci USA. 1993;90:6424-8. (Pubitemid 23207225)
19. Aebi S, et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res. 1996;56:3087-90. (Pubitemid 26199755)
20. Fink D, et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res. 1996;56:4881-6. (Pubitemid 26374423)
21. Ribic CM, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349:247-57. (Pubitemid 36859476)
22. Kim GP, et al. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a national cancer institute-national surgical adjuvant breast and bowel project collaborative study. J Clin Oncol. 2007;25:767-72. (Pubitemid 350002875)
23. Barratt PL, et al. DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study. Lancet. 2002;360:1381-91. (Pubitemid 35341303)
24. Diaz-Rubio E, et al. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol. 2007;25:4224-30. (Pubitemid 47548562)
25. Kelly H, Goldberg RM. Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol. 2005;23:4553-60. (Pubitemid 46196586)
26. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med. 2005;352:476-87.
27. Muller CI, et al. Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO colorectal study group. Int J Colorectal Dis. 2008;23:1033-9.
28. Des Guetz G, et al. Microsatellite instability does not predict the efficacy of chemotherapy in metastatic colorectal cancer. A systematic review and meta-analysis. Anticancer Res. 2009;29:1615-20.
29. Des Guetz G, Uzzan B, Nicolas P, Schischmanoff O, Morere JF. Microsatellite instability: a predictive marker in metastatic colorectal cancer? Target Oncol. 2009;4:57-62.
30. des Guetz G, et al. Microsatellite instability and sensitivity to FOLFOX treatment in metastatic colorectal cancer. Anticancer Res. 2007;27:2715-9. (Pubitemid 47227987)
31. Koopman M, et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer. 2009;100:266-73.
32. Jensen LH, Danenberg KD, Danenberg PV, Jakobsen A. Predictive value of MSH2 gene expression in colorectal cancer treated with capecitabine. Clin Colorectal Cancer. 2007;6:433-5. (Pubitemid 46658517)
33. Choe WH, et al. High frequency of microsatellite instability in intestinal-type gastric cancer in Korean patients. Korean J Intern Med. 2005;20:116-22. (Pubitemid 43109892)
34. Vaisman A, et al. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res. 1998;58:3579-85. (Pubitemid 28376554)
35. Brown R, et al. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene. 1997;15:45-52. (Pubitemid 27348095)
36. Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R. Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res. 2000;60:6039-44.
37. Strathdee G, MacKean MJ, Illand M, Brown R. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene. 1999;18:2335-41. (Pubitemid 29192710)
38. Strathdee G, et al. Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. Am J Pathol. 2001;158:1121-7. (Pubitemid 32221804)
39. Fink D, et al. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res. 1997;57:1841-5. (Pubitemid 27209707)
40. Schernhammer ES, Ogino S, Fuchs CS. Folate and vitamin B6 intake and risk of colon cancer in relation to p53 expression. Gastroenterology. 2008;135:770-80.
41. Munro AJ, Lain S, Lane DP. P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer. 2005;92:434-44. (Pubitemid 40395523)
42. Nehls O, et al. Studies on p53, BAX and Bcl-2 protein expression and microsatellite instability in stage III (UICC) colon cancer treated by adjuvant chemotherapy: major prognostic impact of proapoptotic BAX. Br J Cancer. 2007;96:1409-18. (Pubitemid 46685789)
43. Allegra CJ, et al. Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer. J Clin Oncol. 2002;20:1735-43. (Pubitemid 34273261)